title: Development of Fe3O4-poly(L-lactide) magnetic microparticles in supercritical CO2.
abstract: The Fe(3)O(4)-poly(L-lactide) (Fe(3)O(4)-PLLA) magnetic microparticles were successfully prepared in a process of solution-enhanced dispersion by supercritical CO(2) (SEDS), and their morphology, particle size, magnetic mass content, surface atom distribution and magnetic properties were characterized. Indomethacin (Indo) was used as a drug model to produce drug-polymer magnetic composite microparticles. The resulting Fe(3)O(4)-PLLA microparticles with mean size of 803 nm had good magnetic property and a saturation magnetization of 24.99 emu/g. The X-ray photoelectron spectroscopy (XPS) test indicated that most of the Fe(3)O(4) were encapsulated by PLLA, which indicated that the Fe(3)O(4)-PLLA magnetic microparticles had a core-shell structure. After further loading with drug, the Indo-Fe(3)O(4)-PLLA microparticles had a bigger mean size of 901 nm, and the Fourier transform infrared spectrometer (FTIR) analysis demonstrated that the SEDS process was a typical physical coating process to produce drug-polymer magnetic composite microparticles, which is favorable for drugs since there is no change in chemistry. The in vitro cytotoxicity test showed that the Fe(3)O(4)-PLLA magnetic microparticles had no cytotoxicity and were biocompatible, which means there is potential for biomedical application.
authors.affiliation: College of Materials Science and Engineering, Sichuan University, Chengdu, Sichuan 610064, China.
authors.forename: Ai-Zheng
authors.initials: AZ
authors.lastname: Chen
authors.forename: Yun-Qing
authors.initials: YQ
authors.lastname: Kang
authors.forename: Xi-Ming
authors.initials: XM
authors.lastname: Pu
authors.forename: Guang-Fu
authors.initials: GF
authors.lastname: Yin
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Jun-Yan
authors.initials: JY
authors.lastname: Hu
mesh_terms: D000818:Animals; D001672:Biocompatible Materials; D002245:Carbon Dioxide; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000379:methods*; D005290:Ferric Compounds / Q000737:chemistry*; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage; D008280:Magnetics; D010316:Particle Size; D011091:Polyesters / Q000737:chemistry*
chemical_list: D001672:Biocompatible Materials; D005290:Ferric Compounds; D011091:Polyesters; D002245:Carbon Dioxide; C000499:ferric oxide; C033616:poly(lactide); D007213:Indomethacin